Nonepithelial ovarian cancer – the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)

Authors

  • Cristina Daviu Department of Gynecology and Obstetrics, Zealand University Hospital, Roskilde, Denmark
  • Jan Blaakaer Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Ane Gerda Z. Eriksson Department of Gynecologic Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital; Oslo University Hospital, Oslo, Norway
  • Jørn Herrstedt Department of Clinical Oncology, Zealand University Hospital, Roskilde, Denmark; Institute of Clinical Medicine, Faculty of Health Sciences, Copenhagen University, Denmark
  • M. P. Vandborg Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Anne Mette Odgaard Rasmussen Department of Gynecology and Obstetrics, Zealand University Hospital, Roskilde, Denmark
  • Katrine Fuglsang Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark

DOI:

https://doi.org/10.1080/0284186X.2022.2088249

Keywords:

Nordic countries, nonepithelial ovarian cancer(NEOC), rare cancer, clinical practice

Abstract

Background

Nonepithelial ovarian cancer (NEOC) represents a wide variety of rare tumors. They are often diagnosed at an early stage and have a good prognosis compared to epithelial ovarian cancer. In the Nordic countries, the total annual number of patients diagnosed with ovarian cancer, Fallopian tube cancer or primary peritoneal carcinoma (hereafter ovarian cancer) was 2281 in 2014–2018, of which 3–10% were NEOC. International guidelines for diagnosis, treatment and follow-up have been developed. We present the results of a survey, aiming at clarifying current clinical practice in the Nordic countries.

Material and Methods

Between 09.2020 and 02.2021 a 33-question electronic survey was distributed to 22 hospitals in Finland, Sweden, Norway, Iceland and Denmark via the Nordic Society of Gynecological Oncology (NSGO) National Representatives. Data were collected in a secure web-based software platform. The questionnaire focused on demographics, diagnosis, treatment and follow-up programs.

Results

Twenty-one (95,4%) centers completed the survey. A total of 155 annual new NEOC cases treated in the Nordic countries were reported, corresponding to approximately 7% of all ovarian cancer cases. Most centers measured some or all of the recommended biomarkers routinely. Vaginal ultrasound and computed tomography (CT) were the preferred imaging modalities. The majority of centers conducted multidisciplinary team (MDT) meetings. The primary reported treatment was surgery. In 65% of centers, lymph node dissection was only performed in cases with suspicious lymph nodes. Surveillance was usually offered > four years.

Discussion

Despite, the presence of clinical European guidelines, variation in the current clinical practice amongst participating centers adhering to national guidelines was observed. Prospective clinical national research programs are sparse, and an enhanced cooperation in the Nordic countries toward development of a Nordic guideline and database is highly warranted and a prerequisite for future research, preferably in cooperation with the larger international groups.

Downloads

Download data is not yet available.

Downloads

Published

2022-08-03

How to Cite

Daviu, C., Blaakaer, J., Eriksson, A. G. Z., Herrstedt, J., Vandborg, M. P., Odgaard Rasmussen, A. M., & Fuglsang, K. (2022). Nonepithelial ovarian cancer – the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO). Acta Oncologica, 61(8), 939–945. https://doi.org/10.1080/0284186X.2022.2088249

Issue

Vol. 61 No. 8 (2022): Acta Oncologica

Section

Articles